Q4 2024 Neuropace Inc Earnings Call Transcript
Key Points
- NeuroPace Inc (NPCE) reported a 22% increase in total revenue for 2024, reaching $79.9 million, driven by sales of the RNS system and Dixie Medical SEEG products.
- The company achieved record quarterly revenue in the fourth quarter of 2024, with a 19% growth compared to the same period in 2023.
- NeuroPace Inc (NPCE) successfully executed its three-part strategy, focusing on expanding adoption and utilization within Level 4 comprehensive epilepsy centers, expanding service delivery with Project Care, and expanding indications for the RNS system.
- The company reported positive three-year safety and effectiveness data from its ongoing five-year prospective post-approval study of the RNS system, showing unmatched seizure control.
- NeuroPace Inc (NPCE) completed a public offering, strengthening its balance sheet with net proceeds of approximately $69.8 million, which is expected to support planned operations until achieving cash flow break-even.
- Despite revenue growth, NeuroPace Inc (NPCE) reported a net loss of $5.3 million for the fourth quarter of 2024, compared to a $6.2 million loss in the same period of 2023.
- The company faces material risks and uncertainties that could cause actual results to differ from forward-looking statements, as highlighted in their earnings call.
- Operating expenses increased by 7% in the fourth quarter of 2024, driven by higher R&D and SG&A expenses.
- The gross margin for 2025 is expected to be in the range of 73% to 75%, with potential variability due to fluctuations in the proportion of Dixie Medical revenue.
- NeuroPace Inc (NPCE) needs to work with payers to expand coverage criteria for new indications, which could pose challenges in reimbursement for generalized and pediatric epilepsy markets.
Greetings and welcome to the NeuroPace fourth quarter 2024 earnings call (Operator Instructions)
As a reminder, this conference is being recorded. It is now my pleasure to introduce Jeremy Feffer with LifeSci Advisors. Please go ahead.
Good afternoon.
Thank you for joining us for Neuropace's fourth quarter and full year 2024 Financial and operating results conference call. On today's call, we will hear from Joel Becker, Chief Executive Officer, and Rebecca Kuhn, Chief Financial Officer.
Earlier today, Neuropace released financial results for the 4th quarter and year-ended December 31, 2024. A copy of the press release is available on the company's website at neuropace.com.
Before we begin, I would like to remind you that throughout this call, we will make statements that include forward-looking statements within the meaning of federal securities laws which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
